Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 12 de 12
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Zhonghua Nei Ke Za Zhi ; 58(10): 751-757, 2019 Oct 01.
Artigo em Chinês | MEDLINE | ID: mdl-31594173

RESUMO

Objective: To investigate the characteristics of body composition (BC) in gout patients and its clinical significance. Methods: Consecutive gout patients were recruited between August 2017 and December 2018. Demographic information, clinical characteristics and comorbidities were collected. BC was assessed by bioelectric impedance analysis including body fat percentage (BF%), trunk and limb BF%, appendicular skeletal muscle index. Overfat was defined by BF% ≥25% for male and ≥35% for female. The association between BC and serum uric acid (sUA) was evaluated by multiple linear regression. Results: A total of 362 gout patients were recruited with median age 38 (30, 52) years, 96.1% (348/362) were male. Mean sUA was (551±133) µmol/L. The mean BF% was (25.8±6.4)% with 53.6%(194/362) patients overfat. Male gout patients with overfat showed more affected joints [4(2, 6) vs. 2(2, 5)], higher sUA [(576±126)µmol/L vs. (523±134) µmol/L], higher prevalence of dyslipidemia [70.1%(131/187) vs. 54.0%(87/161)], metabolic syndrome [60.8%(118/187) vs. 28.0%(47/161)], fatty liver [58.2%(113/187) vs. 35.1%(59/161)] and hypertension [44.4%(83/187) vs. 25.5%(41/161)] than male patients with normal fat (all P<0.05). Their BF%, trunk BF% and limb BF% were positively correlated with the numbers of affected joints, sUA, metabolic syndrome, fatty liver, and hypertension, respectively (r=0.154-0.435, all P<0.05). Multivariable linear regression suggested that BF% (ß=4.29, P=0.020) and trunk BF% (ß=9.11, P=0.007), but not limb BF%, were positively correlated with sUA. Conclusion: Overfat is very common in gout patients. The proportion of trunk fat in male patients is positively correlated with sUA. When assessing obesity in gout patients clinically, body composition analysis should be performed simultaneously.


Assuntos
Composição Corporal/fisiologia , Gota/diagnóstico , Obesidade/epidemiologia , Ácido Úrico/sangue , Adulto , Dislipidemias/epidemiologia , Feminino , Gota/sangue , Gota/epidemiologia , Humanos , Hipertensão/sangue , Hipertensão/epidemiologia , Masculino , Pessoa de Meia-Idade , Hepatopatia Gordurosa não Alcoólica/sangue , Hepatopatia Gordurosa não Alcoólica/epidemiologia , Obesidade/sangue , Prevalência
2.
Zhonghua Xin Xue Guan Bing Za Zhi ; 47(5): 374-380, 2019 May 24.
Artigo em Chinês | MEDLINE | ID: mdl-31142081

RESUMO

Objective: To evaluate the efficacy and safety of low dose sublingual nifedipine dripping pills (5 mg) in treating moderate and severe hypertension in comparison with normal dose (10 mg) of sublingual nifedipine dripping pills. Methods: This study was designed as a randomized, double-blind, positive drug parallel controlled, multi-center, non-inferiority clinical trial. Patients with moderate and severe hypertension were enrolled by 14 clinical trial centers, randomly divided into the trial group (sublingual 5 mg nifedipine dripping pills) and the control group (sublingual 10 mg nifedipine dripping pills). The changes in blood pressure were monitored continuously within 2 hours after the initial administration, repeated the dose in 20 minutes interval after the initial administration for up to additional 3 doses (maximum 4 doses) if the antihypertensive efficacy was not satisfactory. The efficacy of antihypertensive therapy between the two groups was evaluated by repeated administration rates and blood pressure changes at 60 minutes post the initial administration, and the safety of treatment was evaluated by recording adverse event rate of the two groups. Results: The anti-hypertensive effective rates at 60 minutes after sublingual administration were 83.5% (202/242) and 86.7% (208/240) respectively between the trial group and control group (χ(2)=1.307, P=0.253) . On the aspect of antihypertensive effectiveness at 60 minutes after single dose of sublingual administration, the anti-hypertension effective rates of the trial group and the control group were 85.6% (154/180) and 87.2% (164/188) respectively (χ(2)=0.221, P=0.639). Prevalence of the repeated administration was also similar between the two groups (25.6%(62/242) in the trial group and 21.7% (52/240) in the control group, χ(2)=1.043, P=0.307). On the safety aspect, there was no adverse events/reactions in the trial group, but there were 15 cases of adverse events/reactions occurred in control group (6.25%, χ(2)=15.611, P<0.001). Conclusions: In the treatment of moderate to severe hypertension, the antihypertensive efficacy of low dose nifedipine dripping pills is similar to that of conventional dosage, and the safety profile of low dose nifedipine dripping pills is better than that of the conventional dose.


Assuntos
Anti-Hipertensivos , Hipertensão , Nifedipino , Administração Sublingual , Anti-Hipertensivos/administração & dosagem , Pressão Sanguínea , Método Duplo-Cego , Humanos , Hipertensão/tratamento farmacológico , Nifedipino/administração & dosagem
3.
Zhonghua Nei Ke Za Zhi ; 58(3): 215-217, 2019 Mar 01.
Artigo em Chinês | MEDLINE | ID: mdl-30803182
4.
Zhonghua Nei Ke Za Zhi ; 57(3): 185-190, 2018 Mar 01.
Artigo em Chinês | MEDLINE | ID: mdl-29518862

RESUMO

Objective: To investigate clinical characteristics and renal uric acid excretion in early-onset gout patients. Methods: Consecutive inpatients with primary gout were recruited between 2013 and 2017. The patients with gout onset younger than 30 were defined as early-onset group while the others were enrolled as control group. Clinical characteristics and uric acid (UA) indicators were compared between two groups. Results: Among 202 recruited patients, the early-onset group included 36 patients (17.8%). Compared with control group, the early-onset group presented more patients with obesity [13 patients (36.1%) vs. 22 patients (13.3%), P<0.05], significantly higher serum UA level [(634±124)µmol/L vs.(527±169)µmol/L] and glomerular load of UA[(7.2±2.8)mg·min(-1)·1.73m(-2) vs. (4.4±2.2)mg·min(-1)·1.73m(-2)] and estimated glomerular filtration rate (GFR) [(83±21)ml·min(-1)·1.73m(-2) vs. (67±21)ml·min(-1)·1.73m(-2)] (all P<0.05), lower fractional excretion of UA [4.4% (3.4%,6.1%) vs. 7.2% (5.2%,9.6%),P<0.05], whereas 24h urinary UA excretion was comparable [(2 788±882)µmol/1.73m(2) vs. (2 645±1 140)µmol/1.73m(2), P=0.274]. Subgroup analysis of patients without chronic kidney disease showed significantly lower fractional excretion of UA in the early-onset group [4.5%(3.3%,6.1%) vs. 6.7% (5.1%,8.7%),P<0.05]. Logistic regression analysis showed that obesity (OR=3.25) and fractional excretion of UA less than 7% (OR=9.01, all P<0.05) were risk factors of gout early onset. Conclusion: The gout patients with early-onset younger than 30 present high serum and glomerular load of uric acid which might be due to obesity and relative under-excretion of renal uric acid.


Assuntos
Gota/metabolismo , Gota/urina , Túbulos Renais/metabolismo , Obesidade/complicações , Ácido Úrico/sangue , Ácido Úrico/urina , Adolescente , Adulto , Taxa de Filtração Glomerular , Humanos , Hiperuricemia , Pessoa de Meia-Idade , Adulto Jovem
5.
Zhongguo Yao Li Xue Bao ; 13(3): 265-7, 1992 May.
Artigo em Chinês | MEDLINE | ID: mdl-1359731

RESUMO

Methyl 5-aminosalicylate hydrochloride (M-5-AS) at the dosages of 21, 42, 209, and 417 mg.kg-1.d-1 ig to mice during d 6-15 of pregnancy, no obvious effects on the placenta, fetus weight, sex differentiation, external appearance, visceral, and skeletal development were observed. In rats ig M-5-AS 56 and 556 mg.kg-1.d-1 produced no noticeable effects on the organogenesis or teratogenesis either. In mice and rats ig salicylazopyridine 410 and 1089 mg.kg-1.d-1 respectively no obvious teratogenicity was detected. However, aspirin 250 mg.kg-1.d-1 ig did bring about significant teratogenicity in rats.


Assuntos
Ácidos Aminossalicílicos/toxicidade , Anti-Inflamatórios não Esteroides/toxicidade , Desenvolvimento Embrionário e Fetal/efeitos dos fármacos , Sulfassalazina/toxicidade , Anormalidades Induzidas por Medicamentos/etiologia , Animais , Perda do Embrião/induzido quimicamente , Feminino , Morte Fetal/induzido quimicamente , Camundongos , Gravidez , Ratos , Ratos Endogâmicos
6.
Yan Ke Xue Bao ; 5(3-4): 118-21, 1989 Dec.
Artigo em Chinês | MEDLINE | ID: mdl-2702174

RESUMO

20 patients with intracranial A.V. malformation with orbital involvement were examined by B-Scan (Real- time ophthascanB). colour doppler (Acason 128) and CT scan. These patients were confirmed in clinically and other examination. Ultrasonography Showed dilated superior ophthalmic vein and its pulsating which are Synchroniged with the heart beating; the echo-free cavity changed in shape upon compression with the probe and some thickened extraocular muscles. The flowing counter pulsating and volume of blood stream were showed clearly in colour doppler. CT scan showed dilated superior ophthalmic vein, thickened extraocular muscles and dilate shadow of cavernous sinus. If strengthen scan to be done, the malformation of cerebrum artery and vein can be showed clearly. These examination are of value in diagnosis. The rate of ultrasound and CT scan for the differential-diagnosis was discussed.


Assuntos
Malformações Arteriovenosas Intracranianas/diagnóstico , Doenças Orbitárias/diagnóstico , Tomografia Computadorizada por Raios X , Ultrassonografia , Adolescente , Adulto , Idoso , Criança , Feminino , Humanos , Malformações Arteriovenosas Intracranianas/complicações , Masculino , Pessoa de Meia-Idade , Doenças Orbitárias/etiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA